Table of contents
June 2017 - Volume 76 - Suppl 2
Annual European Congress of Rheumatology, 14–17 June, 2017
- Speaker Presentations
- Joint EULAR - APLAR session: novel animal models - where no researcher has gone before
- Health professional welcome session
- WIN & HOT session
- Moving towards new criteria in SLE, Sjögren's and APS
- The differential diagnosis of diffuse skin sclerosis and of Raynaud's phenomenon and a practical approach to assessment
- Controling the balance between cancer and autoimmunity
- Fibromyalgia: a disease of the peripheral or central nervous system
- Chondrocyte channels (role in mechanotransduction)or “channeling the chondrocyte”
- Wearable technologies in 21st century healthcare
- Assessment and management of osteoporosis
- Systematic literature review: the link from science to clinical practice
- EULAR Campaign: Don't Delay, Connect Today
- Standing Committee session on paediatric rheumatology
- Ultrasound basic I & II
- Rehabilitation and modern drug treatment - needs and challenges
- Comorbidities: having one RMD is enough - we don't need anything else
- Cytokines and chemokines
- Bringing rheumatology research to the next level: addressing the main challenges of patient partnerships in research and health care service design
- WIN & HOT session
- Treat-to-target in axSpA: reality or utopy?
- Calcium crystal deposition in rheumatic diseases
- Fifty shades of remission in RA
- Innate immunity
- To be and to become: transition from paediatric to adult care
- Heterogeneity in JIA
- EULAR - EMA session
- Barrier free employment for young people with RMDs
- Epidemiology of rheumatic and musculoskeletal diseases - a critical appraisal
- Ultrasound advanced I & II
- PsA: an integrated perspective
- Autoinflammatory diseases in children and adults
- Immunogenicity of biologics; myth or reality?
- Which target/outcome is more relevant in the management of SLE?
- Joint EULAR - EFIS session: Tilting the balance: from disease to tolerance induction
- What to do about comorbidity?
- Data visualisation: tables and graphs for publication and presentation I & II
- Difficult to reach patient groups
- EULAR Projects in musculoskeletal imaging
- Capillaroscopy I & II
- Ultrasound, clinical, diagnostic and therapeutic skills I & II
- Macrophage M2 polarization: implications in fibrotizing diseases
- Mucosal B cells: gatekeepers of immune function
- WIN & HOT session
- Comorbidities in rheumatoid arthritis
- Life-threatening presentation of rheumatic diseases
- AxSpA: From bug to gut and to disease phenotype
- Pregnancy meets rheumatic patients
- Neuronal and hormonal alterations in arthritis
- Fighting osteoporosis fragilities
- Biological agents in juvenile idiopathic arthritis: open issues
- Health equity and economy - a vital relationship
- Biomarkers in cardiovascular rheumatology - state-of-the-art 2017
- MRI I & II
- WIN & HOT session
- What is behind vasculitis?
- Cytokine taxonomy: reflection in the therapy of arthritides and other IMIDs
- Regulatory molecules in connective tissue
- Patient engagement in research: best practices, benefits, and challenges
- RA treatment in patients wanting to become pregnant - interactive session
- Latest advances in the treatment and management of psoriatic arthritis and the latest news on the use of Biosimilars in RMDs
- From pre-RA to established RA
- Laboratory course - from the clinic to the lab and back II
- Switching T on and off: how T cells drive and regulate chronic inflammation
- Reverse translation - learning from clinical trials in SLE, Sjögren's and APS
- Genomic imprinting and post-translational modifications
- Optimizing treatment for osteoarthritis: take the phenotype in account “one size does not fit all”
- Targeting adipose tissue inflammation
- Trials and tribulations of medication adherence
- Outcome in juvenile idiopathic arthritis
- Getting financial support to research in RMDs through horizon 2020: opportunities, good practices, and successful experiences
- EULAR Projects - challenging projects in education and training
- Workshop: strengthening your organisation - how to manage volunteers
- WIN & HOT session
- Systemic sclerosis
- How diet influences musculoskeletal diseases
- Can targeting disease activity in hand osteoarthritis improve our treatment in the 21st century
- Why we do develop autoimmunity
- Closing the gap between objective measures and self-report in fibromyalgia
- Interactive cases from the HOT and WIN sessions
- Suffering in silence. Optimizing the management of psychological well-being for people with RMDs
- Showcasing the EULAR Online Course for Health Professionals
- HPR Highlight session
- Oral Presentations
- Moving towards new criteria in SLE, Sjögren's and APS
- Controlling the balance between cancer and autoimmunity
- Fibromyalgia: a disease of the peripheral or central nervous system
- Chondrocyte channels (role in mechanotransduction) or “channeling the chondrocyte”
- Wearable technologies in 21st century healthcare
- Assessment and management of osteoporosis
- Systematic literature review: the link from science to clinical practice
- EULAR Campaign: Don't Delay, Connect Today
- Standing Committee session on paediatric rheumatology
- Still breaking news on TNF inhibitors in rheumatoid arthritis
- Progress in managment of SpA
- Early diagnosis of systemic sclerosis and myositis: biomarkers and diagnostic tool
- SLE, Sjögren's and APS - clinical aspects
- Osteoporosis treatment gap, new options and new strategies
- Rehabilitation and modern drug treatment - needs and challenges
- Basic and clinical science in paediatric rheumatology
- Impact of rheumatic diseases
- Comorbidities: having one RMD is enough - we don't need anything else
- Risk factors for developing diseases or comorbidities
- Scleroderma, myositis and related ethology
- Novel insights in inflammatory mediators
- Cytokines and chemokines
- Progress in biological treatment of RA
- PsA: a fascinating disease
- More or less imaging in axial SpA?
- Clinical and therapeutical news in systemic sclerosis
- Vasculitis clinical and pathogenic highlights
- HPR mind over matter - patients perspectives
- RA: really a systemic disease?
- Advances in RA and SpA pathophysiology
- Bringing rheumatology research to the next level: addressing the main challenges of patient partnerships in research and health care service design
- Osteoarthritis: new horizons for treatment
- Cellular drivers of inflammation in rheumatic disease
- Joint health & joint damage: a tale of three tissues
- Treat-to-target in axSpA: reality or utopy?
- Calcium crystal deposition in rheumatic diseases
- Fifty shades of remission in RA
- Innate immunity
- To be and to become: transition from paediatric to adult care
- Heterogeneity in JIA
- Barrier free employment for young people with RMDs
- Epidemiology of rheumatic and musculoskeletal diseases - a critical appraisal
- PsA: an integrated perspective
- Immunogenicity of biologics; myth or reality?
- Which target/outcome is more relevant in the management of SLE?
- Joint EULAR - EFIS session: tilting the balance: from disease to tolerance induction
- What to do about comorbidity?
- Difficult to reach patient groups
- Macrophage M2 polarization: implications in fibrotizing diseases
- Mucosal B cells: gatekeepers of immune function
- PsA: the options grow!
- From classics to new: synthetic DMARDs in RA
- New treatments in SLE, Sjögren's and APS
- Axial spondyloarthritis from risk factor to clinical outcomes
- RA - causes and courses
- HPR move to improve
- Gout: advances in diagnosis and management
- Low back pain and fibromyalgia
- PARE abstract session
- Imaging and treamtent response in rheumatology
- From genetics through epigenetics to proteomics: understanding disease mechanisms
- Innovative insights into mechanism of SLE, Sjögren's and APS
- Comorbidities in rheumatoid arthritis
- AxSpA: from bug to gut and to disease phenotype
- Pregnancy meets rheumatic patients
- Neuronal and hormonal alterations in arthritis
- Fighting osteoporosis fragilities
- Biological agents in juvenile idiopathic arthritis: open issues
- Health equity and economy - a vital relationship
- Biomarkers in cardiovascular rheumatology - state-of-the-art 2017
- What is behind vasculitis?
- Cytokine taxonomy: reflection in the therapy of arthritides and other IMIDs
- Personalised care for back pain
- Regulatory molecules in connective tissue
- Patient engagement in research: best practices, benefits and challenges
- Latest advances in the treatment and management of psoriatic arthritis and the latest news on the use of biosimilars in RMDs
- Switching T on and off: how T cells drive and regulate chronic inflammation
- Reverse translation - learning from clinical trials in SLE, Sjögren's and APS
- Genomic imprinting and post-translational modifications
- Optimizing treatment for osteoarthritis: take the phenotype in account “one size does not fit all”
- Targeting adipose tissue inflammation
- Trials and tribulations of medication adherence
- Outcome in juvenile idiopathic arthritis
- Systemic sclerosis
- How diet influences musculoskeletal diseases
- Can targeting disease activity in hand osteoarthritis improve our treatment in the 21st century
- Why we do develop autoimmunity
- Closing the gap between objective measures and self-report in fibromyalgia
- Suffering in silence. Optimizing the management of psychological well-being for people with RMDs
- Showcasing the EULAR Online Course for Health Professionals
- Late Breaking Abstracts
- Poster Presentations
- Genetic basis, egpigenetics an genomics in disease
- Inflammatory mediators in rheumatic disease
- RA disease course and prognosis
- MTX, GCs and JAK inhibitors in RA
- Pathomechanism in SLE, SS, APS
- Novelty in the clinical approach to SLE, Sjögren's and APS I
- Vasculities clinical aspects I
- Progress in managment of spondyloarthritis
- A stroll among the crystals
- Paediatric rheumatology
- Clinicial features and treatment of orphan diseases
- Rheumatology training and disease burden
- Economical impact of biosimilars and sicussing risks with patients
- Outcomes across all rheumatology
- Cytokines and inflammatory mediators
- Rheumatoid arthritis - prognosis, predictors and outcome
- Rheumatoid arthritis - comorbidity and clinical aspects
- Rheumatoid arthritis - non biologic treatment
- SLE, Sjögren's and APS - etiology, pathogenesis and animal models
- SLE, Sjögren's and APS - clinical aspects (other than treatment)
- Vasculitis
- Spondyloarthritis - treatment
- Crystal diseases, metabolic bone diseases and bone diseases other than osteoporosis
- Fibromyalgia
- Basic science in paediatric rheumatology
- Paediatric rheumatology
- Other orphan diseases
- Education
- Public health, health services research and health economics
- Validation of outcome measures and biomarkers
- Rehabilitation
- Guided Poster Tours
- RA stromal cells - reloaded
- RA all over the body
- TNF inhibitors in RA = always and again
- Trends in non-TNF alpha bilogicals for RA I
- Novelty in the clinical approach to SLE, Sjögren's and APS II
- Vasculities clinical aspects II
- Scleroderma and myositis: etiology
- Indexes and predictors in systemic sclerosis and myositis
- New drivers in RA and SpA pathophysiology
- Outcome in AxSpA: does it matter?
- Osteoporosis risk assessment and treatment: new tools and new strategies
- What’s new in orphan diseases
- Imaging advances in arthritis - what is new?
- Risk factors for RMDs or comorbid conditions
- Posters
- Cartilage, synovium and osteoimmunology
- Rheumatoid arthritis - etiology, pathogenesis and animal models
- Rheumatoid arthritis - prognosis, predictors and outcome
- Rheumatoid arthritis - comorbidity and clinical aspects
- Rheumatoid arthritis - anti-TNF therapy
- Rheumatoid arthritis - other biologic treatment
- SLE, Sjögren's and APS - clinical aspects (other than treatment)
- Vasculitis
- Scleroderma, myositis and related syndromes - etiology, pathogenesis and animal models
- Scleroderma, myositis and related syndromes
- Spondyloarthritis - etiology, pathogenesis and animal models
- Spondyloarthritis - clinical aspects (other than treatment)
- Psoriatic arthritis
- Osteoporosis
- Other orphan diseases
- Diagnostics and imaging procedures
- Epidemiology, risk factors for disease or disease progression
- Guided Poster Tours
- Innate mediators and autoantibodies in rhematic disease
- How B and T cells contribute to rheumatic disease
- RA - risk factors and consequences
- From the heart of rheumatology
- Trends in non-TNF alpha bilogicals for RA II
- New treatment options in SLE, Sjögren's and APS
- SSc, myositis and rare diseases: etiology and animal models
- Last news on systemic sclerosis and myositis
- A walk through PsA progress
- Steps forward in osteoarthritis research
- Infection related rheumatic disease: clinical and epidemiologic aspects
- Imaging advances in vasculitis, crystal and connective tissue disease
- Comorbidities and outcomes in RMDs
- Posters
- Innate immunity in rheumatic diseases
- Adaptive immunity (T cells and B cells) in rheumatic diseases
- Rheumatoid arthritis - prognosis, predictors and outcome
- Rheumatoid arthritis - comorbidity and clinical aspects
- Rheumatoid arthritis - anti-TNF therapy
- Rheumatoid arthritis - other biologic treatment
- SLE, Sjögren's and APS - treatment
- SLE, Sjögren's and APS - clinical aspects (other than treatment)
- Scleroderma, myositis and related syndromes - etiology, pathogenesis and animal models
- Scleroderma, myositis and related syndromes
- Spondyloarthritis - clinical aspects (other than treatment)
- Psoriatic arthritis
- Osteoarthritis
- Infection-related rheumatic diseases
- Back pain, mechanical musculoskeletal problems, local soft tissue disorders
- Diagnostics and imaging procedures
- Epidemiology, risk factors for disease or disease progression
- Abstracts Accepted for Publication
- Genomics, genetic basis of disease and HLA/T cell recognition
- Adaptive immunity (T cells and B cells) in rheumatic diseases
- Innate immunity in rheumatic diseases
- Cytokines and inflammatory mediators
- Cartilage, synovium and osteoimmunology
- Rheumatoid arthritis - etiology, pathogenesis and animal models
- Spondyloarthritis - etiology, pathogenesis and animal models
- SLE, Sjögren's and APS - etiology, pathogenesis and animal models
- Scleroderma, myositis and related syndromes - etiology, pathogenesis and animal models
- Basic science in paediatric rheumatology
- Rheumatoid arthritis - prognosis, predictors and outcome
- Rheumatoid arthritis - comorbidity and clinical aspects
- Rheumatoid arthritis - anti-TNF therapy
- Rheumatoid arthritis - other biologic treatment
- Rheumatoid arthritis - non biologic treatment
- SLE, Sjögren's and APS - treatment
- SLE, Sjögren's and APS - clinical aspects (other than treatment)
- Vasculitis
- Scleroderma, myositis and related syndromes
- Spondyloarthritis - treatment
- Spondyloarthritis - clinical aspects (other than treatment)
- Psoriatic arthritis
- Osteoarthritis
- Osteoporosis
- Crystal diseases, metabolic bone diseases and bone diseases other than osteoporosis
- Infection-related rheumatic diseases
- Fibromyalgia
- Back pain, mechanical musculoskeletal problems, local soft tissue disorders
- Paediatric rheumatology
- Other orphan diseases
- Diagnostics and imaging procedures
- Public health, health services research and health economics
- Epidemiology, risk factors for disease or disease progression
- Validation of outcome measures and biomarkers
- Rehabilitation
- Education
- Oral Presentations
- Wearable technologies in 21st century healthcare
- Rehabilitation and modern drug treatment - needs and challenges
- HPR mind over matter - patients perspectives
- What to do about comorbidity?
- HPR move to improve
- Fighting osteoporosis fragilities
- Trials and tribulations of medication adherence
- Closing the gap between objective measures and self-report in fibromyalgia
- Showcasing the EULAR Online Course for Health Professionals
- Poster Presentations
- HPR from top to toe; health professional practice
- HPR interventions (educational, physical, social and psychological)
- HPR measuring health (development and measurement properties of PROs, tests, devices)
- HPR epidemiology and public health (including prevention)
- HPR patients' perspectives, functioning and health (descriptive: qualitative or quantitative)
- HPR professional education, training and competencies
- HPR interventions (educational, physical, social and psychological)
- HPR service developments, innovation and economics in healthcare
- HPR measuring health (development and measurement properties of PROs, tests, devices)
- HPR epidemiology and public health (including prevention)
- HPR professional education, training and competencies
- Nursing and daily practice
- HPR patients' perspectives, functioning and health (descriptive: qualitative or quantitative)
- HPR measuring health (development and measurement properties of PROs, tests, devices)
- HPR service developments, innovation and economics in healthcare
- HPR epidemiology and public health (including prevention)
- HPR interventions (educational, physical, social and psychological)
- HPR measuring health (development and measurement properties of PROs, tests, devices)
- HPR epidemiology and public health (including prevention)
- HPR interventions (educational, physical, social and psychological)
- HPR patients' perspectives, functioning and health (descriptive: qualitative or quantitative)
- HPR service developments, innovation and economics in healthcare
- HPR professional education, training and competencies
- Oral Presentations
- EULAR Campaign: Don’t Delay, Connect Today
- Comorbidities: having one RMD is enough - we don’t need anything else
- Bringing rheumatology research to the next level: addressing the main challenges of patient partnerships in research and health care service design
- Barrier free employment for young people with RMDs
- Difficult to reach patient groups
- PARE abstract session
- Health equity and economy - a vital relationship
- Patient engagement in research: best practices, benefits and challenges
- Latest advances in the treatment and management of psoriatic arthritis and the latest news on the use of biosimilars in RMDs
- Suffering in silence. Optimizing the management of psychological well-being for people with RMDs
- Poster Presentations
- PARE - Poster tour I
- PARE - Poster tour II
- Building patient led organisations
- Arthritis research
- Work and rehabilitation
- Patient information and education
- Best practice campaigning
- Psychosocial support
- Arthritis research
- Best practice campaigning
- Patient information and education
- Building patient led organisations